Despite promising clinical results, copyright's Vyndamax, a therapy for hereditary transthyretin-mediated amyloidosis (hATTR), is facing considerable difficulty from pharmacy benefit managers. These insurers are https://emilietprt977090.educationalimpactblog.com/63608352/the-medication-faces-is-dealing-with-pbm-hurdles-the-look-of-coverage-battles